甘油苯丁酸治疗2例单羧酸转运体8缺乏症患者
本文报告了首例使用甘油苯丁酸(GPB)治疗2例因P321L突变导致单羧酸转运体8(MCT8)缺乏症的14.5岁单卵双胞胎,在13个月内递增剂量用药,观察到甲状腺激素谱改善(高T3降低、低T4升高)和体重增加,但神经认知仅有轻微改善,并出现肝转氨酶升高。
要点
- GPB治疗可降低MCT8缺乏症患者的高T3水平并升高低T4水平。
- 治疗期间患者体重显著增加,同时静息代谢率下降。
- 神经认知仅见轻微改善,且出现肝转氨酶升高。
核心结论
- 在首例GPB治疗MCT8缺乏症的报告中发现甲状腺激素谱和体重指数改善,神经发育变化轻微。
研究设计与样本
- 对2例14.5岁因P321L突变导致MCT8缺乏症的单卵双胞胎进行为期13个月的GPB递增剂量治疗,并记录甲状腺激素、生命体征、人体测量和神经认知功能,用间接测热法测静息代谢率,监测GPB血清代谢物,并在稳定表达MCT8P321L突变的MDCK1细胞中评估NaPB的体外效应,与患者既往使用的DITPA和TRIAC效果比较。
主要发现
- NaPB在MDCK1细胞中恢复突变MCT8表达并增加T3转运进入携带P321L突变的细胞。
- GPB治疗降低了高T3水平并升高了低T4水平。
- 患者体重显著增加,同时静息代谢率降低。
- 仅观察到轻微神经认知改善,包括反射亢进评分和认知功能。
- 血清代谢物未超过毒性范围,但观察到肝转氨酶升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Monocarboxylate transporter 8 (MCT8) deficiency is a rare genetic disease that leads to severe global developmental delay. MCT8 facilitates thyroid hormone (TH) transport across the cell membrane, and the serum TH profile is characterized by high T3 and low T4 levels. Recent studies have shown that the chemical chaperone sodium phenylbutyrate (NaPB) restored mutant MCT8 function and increased TH content in patient-derived induced pluripotent stem cells, making it a potential treatment for MCT8 deficiency. OBJECTIVE: We aimed to assess the efficacy and safety of glycerol phenylbutyrate (GPB) in MCT8 deficiency. METHODS: We treated 2 monozygotic twins aged 14.5 years with MCT8 deficiency due to P321L mutation with escalating doses of GPB over 13 months. We recorded TH, vital signs, anthropometric measurements, and neurocognitive functions. Resting metabolic rate (RMR) was measured by indirect calorimetry. Serum metabolites of GPB were monitored as a safety measure. In vitro effects of NaPB were evaluated in MDCK1 cells stably expressing the MCT8P321L mutation. The effects of GPB were compared to the effects of DITPA and TRIAC, thyromimetic medications that the patients had received in the past. RESULTS: NaPB restored mutant MCT8 expression in MDCK1 cells and increased T3 transport into cells carrying the P321L mutation. GPB treatment reduced high T3 and increased low T4 levels. The patients showed a significant weight gain simultaneously with a reduction in RMR. Only minor neurocognitive improvement was observed, in hyperreflexia score and in cognitive functions. Serum metabolites did not exceed the toxic range, but elevated liver transaminases were observed. CONCLUSION: In the first report of GPB treatment in MCT8 deficiency we found an improvement in TH profile and body mass index, with minor neurodevelopmental changes.
引用
- Zung A, Sonntag N, Schweizer U, et al. Glycerol Phenylbutyrate Treatment of 2 Patients With Monocarboxylate Transporter 8 Deficiency. J Clin Endocrinol Metab. 2024. PMID: 38469646. doi:10.1210/clinem/dgae146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。